High dose thrombin time versus the Activated Clotting Time during cardiopulmonary bypass

Journal of Extra-Corporeal Technology

Volumn 31, Issue 2, 1999, Pages 76-79

  De Jong, M A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Activated clotting time; Cardiopulmonary bypass; Heparin; High dose thrombin time

Indexed keywords

HEPARIN;

ACCURACY; ADULT; AGED; ARTICLE; BLOOD CLOTTING TIME; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPARINIZATION; HUMAN; LABORATORY TEST; MALE; SURGICAL PATIENT; THROMBIN TIME;

EID: 0032703531     PISSN: 00221058     EISSN: 29698960     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Wang JS, Lin CY, Karp RB. Comparison of high-dose thrombin time with activated clotting time for monitoring of anticoagulant effects of heparin in cardiac surgical patients. Anesth Analg. 1994;79:9-13.
2. Turner A, Thompson S, LaDuca F. Monitoring heparin anticoagulation with a modified whole blood thrombin time. AmSECT Proceedings. 1992;102-105.
3. Gravlee GP. Anticoagulation for cardiopulmonary bypass. In: Gravlee GP, Davis RF, Utley JR. Cardiopulmonary Bypass Principles and Practice. Baltimore: Williams & Wilkins. 1993;340-380.
4. Kern SM, Ballantyne R, Sanford DM. An in vitro comparison of two commercially available activated clotting time instruments and the effect of temperature upon the reproducibility of ACT determinations. Am Acad Card Perf Proceed. 1991;12:57-61.
5. Tian L, Coffin S, Sutton R, Murray D, Olson J, Ploessl J. Effect of hypothermia on heparin anticoagulation as measured by activated clotting time and factor Xa inhibition. J Extra-Corpor Technol. 1995;4:192-196.
6. Baugh RF, Deemar KA, Zimmermann JJ. Heparinase in the activated clotting time assay: Monitoring heparin-independent alterations in coagulation function. Anesth Analg. 1992;74:201-205.
7. Huyzen RJ, Oeveren W van, Wei F, Stellingwerf P, Boonstra PW, Gu YJ. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass. Ann Thorac Surg. 1996;62:533-537.
8. Tabuchi N, Njo TL, Tigchelaar I, Huyzen RJ, Boonstra PW, Oeveren W van. Monitoring of anticoagulation in aprotinin-treated patients during heart operation. Ann Thorac Surg. 1994;58:774-777.
9. Huyzen RJ, Harder MP, Gallandat Huet RCG, et al. Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin treated patients. J Cardiothorac Vasc Anesth. 1994;8:153-156.
10. Boks R, Wijers M, Bos E. Clinical experiences with monitoring heparin anticoagulation by HiTT during cardiopulmonary bypass in the presence of aprotinin. J NeSECC. 1995;2:14-19.
11. Wang JS, Lin CY, Hung WT, Karp RB. Monitoring of heparin-induced anticoagulation with kaolin activated clotting time in cardiac surgical patients treated with aprotinin. Anaesthesiology 1992;77:1080-1084.
12. Scott D, Sutton RG, Ploessl J, Pennell B. Correlation of ACT as measured with three commercially available devices with circulating heparin levels during cardiac surgery. J Extra-Corpor Technol. 1995;4:197-200.
13. Zucker ML, Walker C, Jobes D, LaDuca F. Comparison of celite and kaolin based heparin and protamin dosing assays during cardiac surgery: The in vitro effect of aprotinin. J Extra-Corpor Technol. 1995;24:201-207.
14. Bull BS, Korpman RA, Huse WM, et al. Heparin therapy during extracorporeal circulation. Problems inherent existing protocols. J Thorac Cardiovasc Surg. 1975;69:674-684.
15. Despotis GJ, Alsoufiev AL, Spitznagel E, Goodnough LT, Lappas D. Response of kaolin ACT to heparin: Evaluation with automated assay and higher heparin dose. Ann Thorac Surg. 1996;61:795-799.